Analysts cite Stelara exclusivity loss and MedTech competition as key challenges for Johnson & Johnson. Price target revisions: Tim Anderson lowers J&J forecast from $160 to $159. Get Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback